Mersana Therapeutics, Inc. (MRSN)

Market Cap	136.47M
Revenue (ttm)	33.18M
Net Income (ttm)	-70.08M
Shares Out	5.00M
EPS (ttm)	-14.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	117,229
Open	27.45
Previous Close	27.51
Day's Range	27.22 - 27.68
52-Week Range	5.21 - 70.73
Beta	0.62
Analysts	Buy
Price Target	30.38 (+11.28%)
Earnings Date	Nov 14, 2025

About MRSN

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 28, 2017
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: MRSN
• Website: https://www.mersana.com

Financial Performance

In 2024, Mersana Therapeutics's revenue was $40.50 million, an increase of 9.88% compared to the previous year's $36.86 million. Losses were -$69.19 million, -59.69% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price target is $30.38, which is an increase of 11.28% from the latest price.

Price Target

$30.38

(11.28% upside)

Analyst Consensus: Buy